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The binding  of [3H]cGMP (guanosine 3’,5’-monophosphate) to purified bovine adrenal cGMP-stimulated 
phosphodiesterase was measured by Millipore filtration on cellulose ester filter. [3H]cGMP-binding activity was 
enhanced when the assay was terminated in buffer containing 70% of saturated ammonium sulfate to dilute the 
enzyme and wash the filters. The cGMP-binding activity was co-purified with the phosphodiesterase activity. The 
binding of [3H]cGMP to purified enzyme was measured in the presence or absence of the phosphodiesterase 
inhibitor,  1-methyl-3-isobutylxanthine.  I-Methyl-34sobutylxanthine  showed linear competitive inhibition with 
respect to cGMP as substrate in the phosphodiesterase reaction but stimulated the [3H]cGMP-binding activity in 
the binding assay. The stimulatory effect appeared not to be the result of preservation from 13H]cGMP  hydrolysis; 
no cGMP phosphodiesterase activity has been measured under the cGMP-binding assay conditions, in the absence 
or presence of the inhibitor. Half-maximal stimulation by I-methyl-3-isobutylxanthine  occurred in the 5 -  7 pM 
concentration range. The specificity of binding of [3H]cCMP  was investigated by adding increasing concentration 
of unlabeled analogs of CAMP (adenosine 3’,5’-monophosphate) and cGMP. The binding of [3H]cGMP  (50 nM) 
was displaced by unlabeled cGMP and cAMP with the following potency: SO%  displacement was reached at the 
0.1 pM cGMP range and only at a fiftyfold higher cAMP concentration. Our data with comparative series of 
analogs  (e. g.  5’-amino-5’-deoxyguanosine  3’,5’-monophosphate  and  3’-amino-3’-deoxyguanosine  3‘,5‘-mOnO- 
phosphate) showed that the potencies of stimulation of cAMP phosphodiesterase activity parallels displacement 
curves or [3H]cGMP  binding to purified enzyme with no correlation with phosphodiesterase inhibition sequences. 
Those experiments suggest that the cGMP-binding activity is directly related  to the non-catalytic  (allosteric) 
II 
cGMP-bhding site. 
Cyclic  nucleotide  phosphodiesterases  exist  in  multiple 
forms that can be distinguished by  multiple criteria such as 
substrate  specificity,  chromatographic,  immunological  or 
kinetic  properties  and  control  mechanisms.  Phosphodi- 
esterase enzymes have  been  tentatively  classified as Ca2+/ 
calmodulin-sensitive,  cGMP-binding,  CAMP-specific  and 
non-specific cyclic nucleotide phosphodiesterases (for review, 
see [I]). At present, three isozymes of phosphodiesterases ap- 
pear to bind cGMP with high affinity: one type in rat platelets 
or lung [2-41,  another type in rod outer segments [5,  61  and 
finally  the  cGMP-stimulated  phosphodiesterase  present  in 
many  mammalian  tissues  [7 -  101.  However,  among  these 
enzymes only the phosphodiesterase  in rod  outer segments 
and  the  cGMP-stimulated  phosphodiesterase  have  been 
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Abbreviations.  CAMP, adenosine 3’,5’-monophosphate;  cGMP, 
guanosine  3’,5’-monophosphate;  5’GMP, guanosine 5’-monophos- 
phate;  ~’NH-cAMP,  3’-amino-3’-deoxyadenosine  3’,5’-monophos- 
phate;  ~’NH-cGMP,  3’-amino-3’-deoxyguanosine 3’,5’-monophos- 
phate;  ~’NH-cAMP,  5‘-amino-5‘-deoxyadenosine  3‘,5’-monophos- 
phate;  5’NH-cGMP,  5’-amino-5’-deoxyguanosine  3’,5’-monophos- 
phate;  IBMX,  I-methyl-3-isobutylxanthine;  QAE-Sephadex,  qua- 
ternary  diethyl-(2-hydroxypropyl)aminoethyl-Sephadex;  PhMeS02F, 
phenylmethylsulfonyl fluoride. 
Enzymes.  Cyclic  nucleotide  phosphodiesterase  or  3’,5’-cyclic 
nucleotide  5’-nucieotidohydrolase (EC 3.1.4.1  7); 5’-nucleotidase or 
5’-ribonucleotide phosphohydrolase (EC 3.1.3.5). 
purified to apparent homogeneity [5,  11, 121. Immunological 
studies have  shown  that  these two  phosphodiesterases  are 
different proteins [I  31.  The cGMP-binding phosphodiesterase 
activity in rat platelets or rat lung and in rod outer segments 
share the following properties: (i) phosphodiesterase activity 
is  co-purified with  cGMP-binding activity;  (ii) phosphodi- 
esterase activity is separated from protein kinase activity and 
(iii) cGMP-binding activity is stimulated in  vitro by phospho- 
diesterase inhibitors, e.g. 1-methyl-3-isobutylxanthine  [2 -  51. 
We  have reported  previously that: (a) cyclic nucleotide 
analogs can be useful probes of catalytic and regulatory (or 
allosteric) sites on the cGMP-stimulated phosphodiesterase, 
i.e. analogs are found that are potent activators but do not 
bind to catalytic binding sites and vice versa [14, 151, and (b) 
kinetics  in  the  presence  of  cGMP  or  1-methyl-3-iso- 
butylxanthine  (IBMX) also argue in favour of  a distinction 
between allosteric and catalytic binding sites [16]. These data 
were  obtained  with  a  partially  purified  cGMP-stimulated 
phosphodiesterase from rat liver. 
The  cGMP-stimulated  phosphodiesterase  has  been 
purified to apparent homogeneity from respectively bovine 
adrenal tissue [Ill and calf liver [12]. In bovine adrenal, the 
purified enzyme has been reported to bind cGMP assessed by 
Millipore filtration [l  I]. cGMP-binding activity co-migrated 
with phosphodiesterase activity under different experimental 
conditions (e.g. polyacrylamide gradient  gel electrophoresis 
under non-denaturating  conditions Ill]). In the binding of 




been  established  which  type  of  binding  site  (catalytic  or 
allosteric) is involved not has the influence (if any) of  IBMX 
been reported. 
These questions were addressed in the present study with 
the  purified  adrenal  cGMP-stimulated  phosphodiesterase. 
The cyclic nucleotide analogs previously used to map catalytic 
and non-catalytic binding sites [  161 were taken to characterize 
the specificity of the cGMP-binding activity. Our data show 
that the potencies of stimulation of cAMP phosphodiesterase 
activity by  cyclic nucleotides analogs parallels displacement 
curves of [3H]cGMP  binding to purified enzyme with no cor- 





MATERIALS AND METHODS 
Purification of the bovine adrenal cGMP-stimulated 
phosphodiesterase 
The  cGMP-stimulated  phosphodiesterase  was  purified 
from bovine adrenal tissue follows: all operations were carried 
out at 4°C; 300 g whole frozen bovine adrenal tissue were 
homogenized in  a  teflon-glass homogenizer  in  1.2 1 buffer 
containing 20 mM Tris/HCI pH 7.5, 2 mM MgClz, 0.4 mM 
PhMeS02F, 2 mM  benzamine,  5 pM  leupeptin,  25 mg/l 
trypsin inhibitor,  5 mM  2-mercaptoethanol (buffer A)  and 
0.25 M sucrose. The homogenate was centrifuged at  33 000 x g 
for I h and the supernatant was decanted through two layers 
of  cheese cloth. 11 of  the supernatant  was loaded  on to a 
DEAE-cellulose (DE-52) column (30 x 5 cm) equilibrated in 
buffer A.  Phosphodiesterase  activity was  eluted  by  an ex- 
ponential gradient of 0-0.5  M ammonium sulfate in buffer 
A. The fractions with cGMP-stimulated phosphodiesterase 
activity were immediately concentrated by ammonium sulfate 
precipitation  at 60%  saturation and  dialyzed overnight  as 
previously  described  [14].  The  enzyme  was  made  2 mM 
dithiothreitol,  1 mM  EDTA and I5 mM benzamidine prior 
to its application to the cGMP epoxy-activated Sepharose 6 B 
column (12 x 1 cm) prepared as in [ll].  The affinity column 
was first washed with 20 ml20 mM Tris/HCl pH 75500  mM 
NaCl, 1 mM EDTA, 2 mM dithiothreitol (buffer B) and with 
10 ml of buffer B containing 125 mM NaC1. The washed resin 
was warmed to 23°C and rinsed with  buffer  B  containing 
125 mM  NaCl  and  10 pM  CAMP. The  bulk  of  phospho- 
diesterase activity was further  eluted  with the same buffer 
including  10mM CAMP. cAMP  was  removed  from  the 
phosphodiesterase  by  dialysis  in  a  Micro  ultrafiltration 
Amicon cell (8 MC). Specific activity of the affinity purified 
enzyme  ranged  from  60 -  100 pmol  cGMP  hydrolyzed 
x min-'  x mg protein-'  with 40 pM cGMP as substrate. The 
preparation was in a state approaching homogeneity as  judged 
by  polyacrylamide  gel  electrophoresis  in  the  presence  of 
sodium dodecyl sulfate and its mobility corresponded  to an 
apparent of M,  105000 (Fig. 1). 
cGMP-binding  and  phosphodiesterase  activities  comi- 
grated  after  gel  filtration  on  a  Sephacryl  S-200  column 
(90 x 0.9 cm) (data not shown). Since the cGMP-binding assay 
was performed in the presence of bovine serum albumin, the 
enzyme was stored at -  80°C in the presence of bovine serum 
albumin at 2 mg/ml. 
DEA  E-cellulose chromatography ojpurijied cGMP-stimulated 
phosphodiesterase from bovine adrenal tissue 
Purified  cGMP-stimulated  phosphodiesterase  (1  50 pg) 
was applied to a DEAE-cellulose DE-52 column (5 x 0.4 cm). 
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Fig. 1. Sodium dodecyl suljiatelgel electrophoresis ojthe purijied bovine 
adrenal cGMP-stimulated  phosphodiesterase. About  I  pg of  protein 
were applied  to the  10% polyacrylamide  gel  (line b). The relative 
molecular mass based on the migration of polymerase p, bovine serum 
albumin, catalase, lactate dehydrogenase, ferritin (5  pg of each, line 
a) was approximately 105000. The gels were stained with Coomassie 
blue R-250 and destained  by  diffusion first in 20% methanol/lO0/' 
acetic acid and subsequently in 50%  methanol/lO% acetic acid/0.5% 
glycerol solutions 
The  column  was  washed  with  2vol. of  20mM Tris/HCl 
pH 7.5 buffer containing 2 mM MgC12,  0.4 mM PhMeS02F, 
15 mM  benzamidine,  5 pM  leupeptin,  25 mg/l  soybean 
trypsin  inhibitor,  5 mM  2-mercaptoethanol.  Phosphodi- 
esterase and [3H]cGMP-binding activities were co-eluted with 
a linear gradient of NaCl 125 -  500 mM (9 ml :  9 ml). 
Phosphodiesterase assay 
assayed as described in [9]. 
Unless otherwise specified, phosphodiesterase activity was 
cGMP-binding assay 
cGMP binding was determined by  Millipore filtration on 
cellulose ester filter (0.45 pm). Purified phosphodiesterase was 
incubated in 20 mM Tris/HCl pH 7.5,200 mM NaC1, 10 mM 
EDTA, 1 mM dithiothreitol, 0.5 mg/ml bovine serum albumin 
and [3H]cGMP in a final volume of 0.1 ml. Unless otherwise 
specified, incubation was performed at 0°C for 10 min. Each 
sample was diluted with 1 ml of an ice-cold buffer medium 
containing 20 mM Tris/HCl pH 7.5, 1 mM EDTA, 200 mM 
NaCl, 1 mM dithiothreitol (buffer C) and 70% of saturated 
ammonium sulfate and the mixture filtered on cellulose ester 
filters. Filters were then washed twice with 4 ml of  the same 
buffer and counted by liquid scintillation in 6 ml of Insta-Gel. 
Phosphodiesterase  activity  under  the  cGMP-binding  assay 
conditions  was  not  detectable:  purified  phosphodiesterase 61 
was incubated in the binding assay mixture; after 10 min at 
O“C, the pH of the medium was decreased to pH 3 with 40 mM 
phosphoric acid to block any hydrolytic activity. In control 
experiments, with  the purified  cGMP-stimulated  phospho- 
diesterase incubated in a standard phosphodiesterase mixture 
at 30°C [9], we  have checked that lowering the pH did in- 
deed  block  phosphodiesterase  activity.  After  addition  of 
phosphoric  acid  to pH 3,  the  separation  of  cGMP from 
its eventual reactions product  5‘GMP was achieved by  two 
independent procedures:  (a) the samples were applied  to a 
reversed phase column (Bondapak CI8/porasil B) of  0.3 ml 
from which  [3H]5’GMP was eluted with 1 ml 1% methanol 
in 10 mM KH2P04/H3P04  buffer at pH 3 and subsequently 
[3H]cGMP  eluted with 1 ml 50% methanol in the same buffer 
[17];  or (b) the samples were neutralized at pH 7.5 withNaOH, 
incubated with an excess of 5’-nucleotidase at 30°C for 20 min 
an chromatographed  on QAE-Sephadex A-25 as in [9]. By 
these  two  methods,  under  binding  assay  conditions,  no 
phosphodiesterase activity (less than 0.5% cGMP hydrolysis) 
was  measured  with  the  purified  cGMP-stimulated 
phosphodiesterase in the presence or in the absence of IBMX. 
The  identity  of  bound  cGMP  to  the  cGMP-stimulated 
phosphodiesterase  was checked by  high-performance liquid 
chromatography  on a  LiChrosorb  10 RP 18 column;  the 
mobile phase was 10 mM KH2P04/Na2HP04  in 10% meth- 
anol at pH 6.5 [18]. 
Polyucrylamide gel electrophoresis 
Sodium dodecyl sulfate gel electrophoresis was performed 
by  the method of Laemmli [I91 using a 10% resolving gel and 
a 5% stacking gel 1.5-mm thick. Electrophoresis was carried 
out at 4°C for 6 h at 150 V. 
Protein determination 
method of Lowry [20] using bovine serum albumin 
from Serva) as standard. 
Protein  determinations  were  carried  out according  the 
pure 
Mate  rials 
[8-3H]cGMP (specific activity 15 Ci/mmol) was obtained 
from Amersham International  and purified on a 0.5 ml re- 
versed-phase column (Bondapak C 18/porasil B) equilibrated 
with  3 ml  20 mM  Tris/HCl  pH 7,  1% methanol.  15 p1  [8- 
3H]cGMP diluted to 200 pl with 20 mM Tris/HCl pH 7 were 
applied to the column.  The column was washed with  1 ml 
20 mM Tris/HCI pH 7, 1  YO  methanol. [3H]cGMP was eluted 
with 2 ml20 mM Tris/HCl pH 5, 5%  methanol and the radio- 
active fractions were pooled [17]. CAMP,  cGMP, S’GMP and 
guanosine  were  purchased  from  Boehringer  (Mannheim). 
DEAE-cellulose (DE-52) was from Whatman. Cellulose ester 
filters (HAWP 293 24) were from Millipore. 5’-Nucleotidase 
(Crotalus atrox venom), PhMeS02F, IBMX, leupeptin  and 
dithiothreitol were purchased  from  Sigma Chemical Com- 
pany (St Louis). Bondapak C18/Porasil B,  35-75  lm, was 
obtained  from  Waters  Associates  Inc.  (Milford).  QAE- 
Sephadex A-25, epoxy-activated Sepharose 6 B and relative 
molecular  mass  standards  for  electrophoresis  were  from 
Pharmacia  (Uppsala). Insta-Gel  was  from  Packard.  Fatty- 
acid-poor bovine albumin  pure) was purchased  from 
Serva  (Heidelberg).  ~’NH-cAMP, ~’NH-cGMP, 5’NH- 
CAMP,  5’NH-cGMP,  purine  ribonucleoside  3’,5’-mono- 
phosphate  and  benzimidazole  ribonucleoside  3‘,5’-mono- 
I 
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Fig.  2.  Displacement  of’  (3HJcGMP binding  to  purified  GMP- 
stimulatedphosphodiesterase  by unlabeled compounds. The enzyme was 
incubated for  10 min  at 0°C in the presence of  50 nM  [3H]cGMP 
and increasing concentrations of unlabeled cGMP (  W),  cAMP (A), 
S’GMP (A)  and guanosine (0).  The binding assay was conducted as 
outlined in Materials and Methods in the presence of 1 mM IBMX. 
Results are the means of triplicates and are expressed as a percentage 
of control activity f  SEM (the control activity is [3H]cGMP bound 
in the absence of unlabeled cyclic nucleotide). The data are  representa- 
tive of experiments with three different preparation of purified enzyme 
phosphate were synthesized as published previously [21-  241 
and kindly provided by Dr B. Jastorff (University of Bremen). 
RESULTS 
General characterization of’ [  HIcGMP binding 
to the purijfed cGMP-stimulated phosphodiesterase 
The  binding  of  [3H]cGMP to  the  purified  phosphodi- 
esterase was examined by Millipore filtration as described in 
Materials and Methods. The following experiments were done 
in the presence of  1 mM IBMX in the incubation medium. 
Under  these  assay  conditions :  the  binding  reaction  of 
[3H]cGMP was time-dependent and reached a plateau  after 
5-  10 min. By  the mere addition of 70% of saturated ammo- 
nium sulfate in the stop and wash buffer (i.e. buffer C: 20 mM 
Tris/HCl  pH 7.5,  200mM  NaCl,  1 mM  EDTA,  1 mM 
dithiothreitol), the [3H]cGMP-binding activity was increased 
by 150% (not shown). We therefore systematically used those 
conditions in all our binding assays. The binding of 50 nM 
[3H]cGMP to the purified phosphodiesterase  was displaced 
by unlabeled cGMP and cAMP with the following potency: 
50% displacement was reached at 0.1 pM cGMP but only at 
fiftyfold higher CAMP  concentration. In contrast, [3H]cGMP 
binding  was  not  displaced  by  5’GMP or guanosine in  the 
0.01 -  100 pM range (Fig. 2). 
Stimulation by IBMX of (3H]cGMP-binding activity 
to the purified cGMP-stimulated phosphodiesterase 
The purified bovine adrenal cGMP-stimulated phospho- 
diesterase exhibited properties similar to those reported pre- 
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Fig. 3. Inhibitory effect of IBMX on cGMP hydrolysis by the adrenal 
cGMP-stimulated phosphodiesterase (double-reciprocal plot). Activity 
was measured in the 5 -  200 pM range for cGMP. The inset shows 
the replot of the slopes of the primary plot as a function of inhibitor 
concentrations. li is expressed as mmol x min-’ x mg protein-’ 
CAMP, cAMP phosphodiesterase activity was stimulated by 
increasing the concentration of cGMP: a twofold stimulation 
of cAMP phosphodiesterase activity occurred generally in the 
0.1 pM cGMP range (Table 1).  The enzyme displayed positive 
homotropic cooperativity  with a Hill coefficient of  1.9 for 
cAMP hydrolysis (not shown). In contrast, on a fully activated 
enzyme, with cAMP as variable substrate and in the presence 
of 3 pM cGMP, double-reciprocal plots of cGMP-stimulated 
phosphodiesterase were linear. Michaelian kinetics were also 
observed with cGMP as substrate in the 5 -  200 pM range. 
Inhibition by IBMX was shown to be competitive with respect 
to cGMP. A replot of the slopes of  the primary reciprocal 
plot  was  linear  and  a  Ki  value  of  8 pM  for  IBMX  was 
calculated (Fig. 3, inset). 
The influence of  IBMX  on cGMP-binding activity was 
studied with the purified phosphodiesterase.  In the binding 
assay, no hydrolysis of cGMP was detected in the presence or 
absence of  IBMX (see Materials and Methods). [3H]cGMP- 
binding  activity  was  stimulated  in  the  presence  of  1 mM 
IBMX  in  the  incubation  medium.  Stimulation  of  cGMP 
binding  at 50 nM  [3H]cGMP appeared  at a concentration 
as low as 3 pM  IBMX and was maximal at 100 pM. Half- 
maximum  stimulation occured  in the  5-7  pM  range with 
three different phosphodiesterase preparations (Fig. 4, inset). 
When  purified  cGMP-stimulated  phosphodiesterase  was 
applied to a DEAE-cellulose column, the phosphodiesterase 
activity as well as the basal and  IBMX-stimulated  cGMP- 
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Fig. 4. DEAE-cellulose chromatography  of  purified cGMP-stimulated 
phosphodiesterase from bovine adrenal  tissue. Enzyme (1 50 pg)  was 
applied to DEAE-cellulose column (0.4 x 5 cm) and was eluted by a 
linear gradient of NaCl 125 -  500 mM (9 ml:  9 ml) starting at fraction 
11. Fractions  of  300 p1  were collected.  Phosphodiesterase  activity 
(A-  - -  -A)  and cGMP-binding activities in the absence (0-0) 
or in the presence (0-0)  of 1 mM IBMX were measured as 
described in Materials and Methods). Phosphodiesterase activity was 
assessed at 40 pM cGMP as substrate and expressed as pmol cGMP 
hydrolyzed x 5 pi- I  x 5 min- ’.  Binding  activity  was  measured  at 
50 nM [3H]cGMP  in the absence or in the presence of 1 mM IBMX 
and expressed as pmol cGMP bound x 80 pl-  x 10 min-  The inset 
shows the dose-response curve between 50 nM [3H]cCMP-binding 
activity  and  the  concentration  of  IBMX.  Results  (triplicates) are 
expressed as pmol cGMP bound/mg protein  SEM 
binding activities co-migrated  by  elution with  a linear salt 
gradient (Fig. 4). 
The potencies of stimulation of  cAMP phosphodiesterase 
activity parallels displacement curves of [3HJcGMP  binding 
to purified cGMP-stimulated  phosphodiesterase 
As with the crude rat liver cGMP-stimulated  phospho- 
diesterase [14], the purified enzyme from bovine adrenal was 
stimulated by cyclic nucleotide derivatives in a concentration- 
dependent manner. These data were obtained in the absence 
of cGMP and at 3 pM cAMP substrate level  (Fig. 5A and 
Table 1). We  previously compared  the inhibition pattern of 
phosphodiesterase activity to the activating potencies of cyclic 
nucleotide  analogs.  In  particular,  3’-amido  and  5’-amido 
derivatives  of  cAMP and  the  two  base-modified analogs, 
benzimidazole  ribonucleoside  3’,5’-monophosphate  and 
purine nucleoside 3’,5’-monophosphate, were used as a tool 
to distinguish  between  catalytic  and  non-catalytic  binding 
sites [14, 151. In the present study, we have compared activa- 
tion and inhibition of phosphodiesterase  activity to binding 
studies in which analogs were tested as competitors of labeled 
cGMP binding. Those binding experiments were performed 
at 30-  60 nM [3H]cGMP with increasing concentrations  of 
unlabeled analog in the 0.01 -  100 pM range. A typical exper- ACTIVATION 
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Fig. 5. Dose-response between the activation of  cAMP  phosphodiesterase  activity at 3 pM and the concentration of  unlabeled 3’NH-cGMP and 
5”H-cGMP  (A) and displacement  of 40 nM [3H]cGMP binding  to purified  enzyme by 3’NH-cGMP and 5’NH-cGMP  (B). (A) Results 
(triplicates) are expressed as a percentage of control values f  SEM (control measured without analog). (B) The binding assay is conducted 
in the presence of 1 mM IBMX. Results (triplicates) are expressed as in Fig. 4 f  SEM 
iment is illustrated in Fig. 5B with 3’NH-cGMP and 5’NH- 
cGMP.  Fig. 5A  compares  the  same  analogs  tested  as 
activators of cAMP phosphodiesterase activity. 3’NH-cGMP 
was  less  potent  than  5’NH-cGMP  as  an  inhibitor  of 
phosphodiesterase activity (Table 1). This was in contrast to 
the binding data where 3‘NH-cGMP did preferentially dis- 
place cGMP binding relative to 5’NH-cGMP. 50% displace- 
ment was obtained at 0.03 pM and 1.5 pM for 3’NH-cGMP 
and  5’NH-cGMP,  respectively  (Table 1,  Fig. 5 B).  3’NH- 
cGMP was also more potent, relative to SNH-cGMP, when 
checked as an activator (Table 1, Fig. 5A). 
A similar conclusion was reached from  the comparison 
between 5’NH-CAMP  and 3’NH-CAMP  (Table 1). cBIMP was 
also  more  potent  than  cPMP  as  an  activator  of 
phosphodiesterase activity, but in contrast the inhibition pat- 
tern  of  phosphodiesterase  activity was  reversed. However, 
the [3H]cGMP-binding activity was displaced by  the same 
sequence as the stimulation of  enzyme activity (Table 1). 
DISCUSSION 
The  purification  of  bovine  adrenal  cGMP-stimulated 
phosphodiesterase  is  achieved  by  DEAE-cellulose  chro- 
matography,  ammonium  sulfate  precipitation  and  affinity 
chromatography on cGMP-Sepharose. Elution of the column 
is performed in two steps: with 10 pM CAMP, no phospho- 
diesterase activity is released from the column but a protein- 
staining band at a relative molecular mass of approximately 
48000 (not shown). The bulk of phosphodiesterase activity is 
further and identically eluted with 10 mM of either cGMP or 
CAMP. Sodium dodecyl sulfate/polyacrylamide  gel electro- 
phoresis reveals a single protein-staining band with a relative 
molecular mass of approximately  105  000 in agreement with 
the previous report of Martins et al. [l  11.  Phosphodiesterase 
and cGMP-binding activities comigrate after DEAE-cellulose 
chromatography, suggesting that both activities reside in the 
same molecule. 
Table 1. Binding, activation and inhibition properties of  cyclic nucleotide 
analogs 
Analogs tested in the 0.01 -  100 pM range. The data are representative 
of  experiments with three different preparations  of purified enzyme 
and are expressed as means  SEM. Binding is  expressed as the 
concentration  necessary to reach 50% displacement of  30 -  60 nM 
[3H]cGMP binding.  Activation  is  expressed  as the  concentration 
necessary to reach a twofold stimulation of phosphodiesterase activity 
at 3 pM CAMP; n.d.,  no detectable  activation  with  5’NH-CAMP. 
For inhibition, cGMP phosphodiesterase activity was measured with 
10 FM cGMP substrate level in the presence or absence of analog. 
Results are expressed as a percentage of control (cGMP enzymatic 
hydrolysis without any addition as in [34]). cBIMP, benzimidazole 
ribonucleoside  3’,5’-monophosphate;  cPMP, purine ribonucleoside 
3’,5’-monophosphate 
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The  binding  of  [3H]cGMP  to  the  cGMP-stimulated 
phosphodiesterase measured by Millipore filtration is largely 
dependent on the experimental conditions. In particular, it is 
increased by  the mere addition of 70% of saturated ammo- 
nium sulfate in the stop and wash buffer after the incubation 
is terminated. The same procedure has been previously used 
in a cGMP assay to increase the binding  of  cGMP to the 
lobster cGMP-dependent protein kinase ([26] and Decoster, 
personal communication). Likewise, studies with bovine lung 
cGMP-dependent  protein  kinase  have  shown  that  cGMP 
bound  to one of the two types of binding sites dissociates 64 
rapidly and  that the inclusion of ammonium sulfate in the 
wash buffer prevents this phenomenon [27,  281. 
The properties of the purified adrenal phosphodiesterase 
appear similar if  not identical to those of partially purified 
cGMP-stimulated phosphodiesterase in rat liver supernatant 
and particulate fractions [14, 15, 291.  cGMP and its analogs 
stimulate cAMP hydrolysis and kinetics with respect to cAMP 
or cGMP as substrate show positive homotropic  coopera- 
tivity. With the partially purified rat liver enzyme, we reported 
that inhibition and activation potencies of multiple analogs 
of cyclic nucleotides were not correlated [14-  161. These data 
argued in favour of a distinction between catalytic and non- 
catalytic  (allosteric)  binding  sites.  In  this  study,  we  have 
addressed the question of whether the cGMP-binding activity, 
measured by Millipore filtration, results from an interaction 
ofcGMP to the allosteric site or to the catalytic site. As shown 
here, the cGMP-binding activity is enhanced in the presence 
of the phosphodiesterase inhibitor, IBMX. The mechanism of 
stimulation is  unknown. It does not result from preservation 
of  cGMP  hydrolysis  by  IBMX,  because  no  hydrolysis  of 
cGMP is being measured under our binding assay conditions. 
IBMX shows linear competitive  inhibition  with  respect  to 
the substrate of  the phosphodiesterase  reaction.  Moreover, 
increased binding activity in  the presence of  IBMX is  not 
reversed  by  increasing  the  concentration  of  the  phospho- 
diesterase inhibitor  (up to  1 mM IBMX). Thus, it  is sug- 
gested that  the binding  of  cGMP results  from  its interac- 
tion at non-catalytic binding sites. This is further confirmed 
by  means of  cyclic nucleotide analogs. The cGMP-binding 
activity is cGMP-specific relative to CAMP.  Moreover the use 
of  cyclic  nucleotide  analogs shows  that  cGMP binding  is 
displaced  with  a  sequence  that  is  not  comparable  with 
phosphodiesterase inhibition sequence. For example, 3’NH- 
cGMP is less  potent  than  5’NH-cGMP as an inhibitor  of 
phosphodiesterase activity. This is in contrast to the binding 
data which shows that 3’NH-cGMP does preferentially dis- 
place cGMP binding relative to S’NH-cGMP. 3’NH-cGMP 
is  also  more  potent  as  an activator  of  phosphodiesterase 
activity. A similar conclusion is reached from the comparison 
between benzimidazole ribonucleoside 3’,5‘-monophosphate 
and  purine  ribonucleoside  3’,5‘-monophosphate.  Our  data 
with comparative series of analogs show that the potencies 
of stimulation of cAMP phosphodiesterase  activity parallels 
displacement curves of 13H]cGMP  binding to purified cGMP- 
stimulated phosphodiesterase. Those experiments suggest that 
the  cGMP-binding  activity  is  measured  on  non-catalytic 
(allosteric) binding sites. 
Stimulation  by  IBMX of cGMP-binding observed with 
the adrenal phosphodiesterase is reminiscent of  other forms 
of phosphodiesterases in rat platelets or lung and in rod outer 
segments [2-  51.  They also display a cGMP-binding activity 
which is co-purified with a phosphodiesterase activity. How- 
ever, by multiple criteria, these enzymes are different proteins. 
For example, only the adrenal form is sensitive to stimulation 
by cGMP in the phosphodiesterase reaction. Recent immuno- 
logical studies have  also shown  that  the adrenal  phospho- 
diesterase is antigenically distinct from the rod outer segment 
cGMP-binding phosphodiesterase [13]. Thus so far, as shown 
here,  the  only  common  characteristic  between  these 
phosphodiesterase multiple forms is the IBMX stimulation of 
[3H]cGMP binding. 
The relationship  between  stimulation of  cGMP-binding 
and inhibition  of phosphodiesterase  activities is  at present 
unknown. In rod outer segments, a heat-stable trypsin-labile 
factor  is  able  to  inhibit  phosphodiesterase  activity  and  to 
stimulate  the  binding  of  cGMP  to  the  cGMP-binding 
phosphodiesterase  [6, 291.  Activators  of  the  latter  enzyme, 
i. e. light and GTP, can almost completely reverse the two 
reciprocal effects of the inhibitor factor [29]. It is not known 
whether  such  a  factor  could  also  control  binding  and 
hydrolytic activity associated to the adrenal cGMP-stimulated 
phosphodiesterase. 
We  have previously proposed  a model for the chemical 
interactions  between  cGMP and  the  non-catalytic  cGMP 
binding site [14].  These interactions were hypothetical because 
they were based on the assumption, validated in the present 
study,  of  a  correlation  between  binding  and  phosphodi- 
esterase activation.  It is now  possible  to directly compare 
binding of analogs to activation and to assess the activation 
mechanism of cGMP in terms of chemical interactions. 
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